BridgeBio have demonstrably improved this course of a novel therapy for amyloid heart disease, here leveraging Attruby. Initial trial results indicates potential outcomes for individuals affected by a debilitating disease. The emphasis represents BridgeBio's commitment to addressing significant healthcare needs in a heart disease field. Attruby: B